Phosphorylation of Nrf2 at Multiple Sites by MAP Kinases Has a Limited Contribution in Modulating the Nrf2-Dependent Antioxidant Response

Zheng Sun¹, Zheping Huang¹,2, Donna D. Zhang¹*

¹ Department of Pharmacology & Toxicology, College of Pharmacy, University of Arizona, Tucson, Arizona, United States of America, ² Department of Pediatrics, Division of Biology and Medicine, Brown University, Providence, Rhode Island, United States of America

Abstract
The bZIP transcription factor Nrf2 has emerged as a pivotal regulator of intracellular redox homeostasis by controlling the expression of many endogenous antioxidants and phase II detoxification enzymes. Upon oxidative stress, Nrf2 is induced at protein levels through redox-sensitive modifications on cysteine residues of Keap1, a component of the E3 ubiquitin ligase that targets Nrf2 for ubiquitin-dependent degradation. The mitogen activated protein kinases (MAPKs) have previously been proposed to regulate Nrf2 in response to oxidative stress. However, the exact role of MAPKs and the underlying molecular mechanism remain poorly defined. Here we report the first evidence that Nrf2 is phosphorylated in vivo by MAPKs. We have identified multiple serine/threonine residues as major targets of MAPK-mediated phosphorylation. Combined alanine substitution on those residues leads to a moderate decrease in the transcriptional activity of Nrf2, most likely due to a slight reduction in its nuclear accumulation. More importantly, Nrf2 protein stability, primarily controlled by Keap1, is not altered by Nrf2 phosphorylation in vivo. These data indicate that direct phosphorylation of Nrf2 by MAPKs has limited contribution in modulating Nrf2 activity. We suggest that MAPKs regulate the Nrf2 signaling pathway mainly through indirect mechanisms.

Introduction
Disruption of redox homeostasis is associated with the toxic effects of many environmental insults and pathogenesis of age-related diseases such as cancer and neurodegenerative disorders [1,2,3,4,5]. Mammalian intracellular redox homeostasis is maintained mainly through transcriptional control of an array of antioxidative genes upon exposure to environmental insults that generate oxidative stress. As a key component of such a control system, the antioxidant response element (ARE) is a conserved cis-acting element found in the promoter regions of many genes encoding antioxidants and detoxification enzymes. The corresponding trans-acting factor for the ARE is the nuclear factor erythroid 2-related factor 2 (Nrf2), a protein belonging to the bZIP (basic-leucine zipper) transcription factor family [6,7,8].

The Nrf2-ARE system is responsible for both basal and inducible expression of many genes involved in antioxidant responses, such as NAD/P[H] quinone oxidoreductase 1 (NQO1), heme oxygenase-1 (HO-1), glutathione S-transferase A1 (GSTA1, also known as GST-Ya in mouse), glutamate-cysteine ligase (also known as γ-glutamylcysteine synthetase, i.e. γGCS) modifier subunit (GCLM) and catalytic subunit (GCLC) [9,10,11,12]. The importance of the Nrf2-ARE system is evidently demonstrated by findings that Nrf2 knockout mice display significantly increased sensitivity to chemical toxicants and carcinogens [13,14].

Nrf2 is activated by a plethora of stress inducers, phyto-antioxidants, and pathological conditions. The current model of the molecular mechanism for Nrf2 activation is that oxidative stress modifies cysteine residues of Keap1, a component of the E3 ubiquitin ligase that targets Nrf2 for degradation, resulting in compromised E3 activity and enhanced Nrf2 protein stability. The subsequent elevation in Nrf2 protein levels leads to Nrf2 nuclear accumulation, increased ARE-Nrf2 binding, and transactivation of its downstream genes [15,16,17,18,19,20,21]. In addition to the primary mode of regulation on its protein stability controlled by Keap1, Nrf2 is also regulated at multiple levels such as nucleocytoplasmic trafficking, acetylation, and phosphorylation [22,23,24,25].

The mitogen-activated protein kinases (MAPKs) are a family of highly related kinases consisting of the extracellular signal-regulated protein kinases (ERKs), the c-jun N-terminal kinases (JNKs), the p38 kinases and other relatively less characterized kinases, all of which catalyze phosphorylation on either serine or threonine residues adjacent to a proline residue. MAPKs are activated in a cascade fashion, by MAP2Ks (also known as MKKs or MEKs) that are in turn activated by MAP3Ks (also known as MEKks, including ASK1, TAK1, Rafs, etc.) [26]. The MAPK signaling system responds to diverse stimuli, including oxidative stress, and has been implicated in Nrf2 induction by many previous reports (Table 1, see Discussion) [24,25]. However previous studies failed to address
whether the observed effects of MAPKs on Nrf2 are through direct and specific phosphorylation events on Nrf2 or through indirect and less specific mechanisms. It is not even known whether or not MAPKs phosphorylate Nrf2 in vivo at all. Another question that remains unanswered is whether MAPKs affect Keap1-mediated control of Nrf2 protein stability in vivo. Therefore, the exact role of MAPKs in Nrf2 activation, as well as the underlying molecular mechanism, remains poorly understood.

Here we report the first evidence indicating that Nrf2 is phosphorylated at several serine and threonine residues by MAPKs in vivo. Combined alanine substitution of those residues leads to only a very moderate decrease in the transcriptional activity of Nrf2, most likely due to a slight reduction in its nuclear accumulation. More importantly, Nrf2 protein stability, which is primarily controlled by Keap1, is not altered in vivo by Nrf2 phosphorylation. These data indicate that direct phosphorylation of Nrf2 by MAPKs has limited contribution in modulating the Nrf2 signaling pathway. We propose that MAPKs regulate Nrf2 mainly through indirect mechanisms.

### Materials and Methods

**Recombinant DNA molecules**

Plasmids expressing JNK1/2, ERK2, p38, MEKK3 and MEKK4 were generous gifts from Dr. Richard R. Vaillancourt at University of Arizona. Plasmids for HA-Nrf2 and Keap1-CBD proteins have been previously described [27]. The Nrf2 mutants were generated by site-directed mutagenesis using the PCR and DpnI-based method as described before [28]. The human NQO1-ARE TATA-Inr luciferase reporter plasmid and the mouse GSTA1-ARE TATA-Inr luciferase reporter plasmid were reported previously [28,29]. Renilla luciferase plasmid pGL4.74[hRluc/TK] was purchased from Promega.

**Cell culture, transfection and chemicals**

HEK293T, MDA-MB-231 and NIH3T3 cells were purchased from ATCC. Cells were maintained in either Dulbecco's modified Eagle's medium (DMEM) or Eagle's minimal essential medium (MEM) in the presence of 10% fetal bovine serum (FBS).

### Table 1. Summary of key findings by previous studies showing the involvement of MAPKs in Nrf2 activation.

| Manipulation of MAPKs | Readout of Nrf2 activity | Changes of Nrf2 activity | Nrf2 inducers | Ref |
|-----------------------|--------------------------|--------------------------|---------------|-----|
| PD98059 or DN ERK2    | NQO1 enzyme, GSTA1 ARE-luc | 30–60% decrease | tBHQ, SF | [42] |
| PD98059 and SB202190  | GCS mRNA, ARE-luc, ARE binding | ~100% decrease | PDTC | [43] |
| MEKK1, TAK1, ASK1, MKK4/6, JNK1 | GSTA1 ARE-luc | 3–18 fold increase | | [44] |
| p38                  | GSTA1 ARE-luc | 30–40% decrease | tBHQ | [44] |
| SB2O3580, DN p38 or DN MKK3 | NQO1 enzyme, GSTA1 ARE-luc | 40–50% increase | BHA, SF, β-NF | [45] |
| SB2O2191 or DN p38   | HO-1 E1-luc | 70–80% decrease | CdCl2 | [46] |
| PD98059, DN JNK1/2 or DN ERK1/2 | HO-1 E1-luc | no change | CdCl2 | [46] |
| PD98059 and SB202191 | nuclear Nrf2 protein | 80–90% decrease | PDTC | [34] |
| JNK1                 | ARE-luc | ~6 fold increase | PEITC | [47] |
| DN JNK1              | ARE-luc | 20–70% decrease | PEITC | [47] |
| MEKK1, TAK1, ASK1, MEK1/5, ERK2/5 | ARE-luc | 1.5–5 fold increase | | [35] |
| U0126 or ERK1 knockout | ARE-luc, ARE binding, Nrf2 protein | block induction | hyperoxia | [48] |
| SP600125 or SB203580 | Nrf2 protein | block induction | gallic acid | [49] |
| Raf knockout         | Nrf2 nuclear entry | no change | curcumin | [50] |
| p38x, β, γ, δ        | HO-1 promoter-luc | 20–80% decrease | SF | [33] |
| U0126, DN ERK2 or DN JNK1 | ARE-luc | 20–60% decrease | BHA | [51] |
| MKK4 and JNK1        | ARE-luc, HO-1 | 3 fold increase | PEITC | [52] |
| DN ERK2 or DN JNK1   | ARE-luc | 40–50% decrease | PEITC | [52] |
| PD98059 and SB203580 | nuclear Nrf2 protein | block induction | 4-HNE | [53] |
| U0126 or DN MEK      | nuclear Nrf2 protein | block induction | PGG | [54] |
| PD169316 or p38 siRNA | HO-1 protein, nuclear Nrf2 protein | >50% decrease | PDT | [55] |
| PD98059 or SB203580  | Nrf2 nuclear entry | block induction | quercetin | [56] |
| PD98059 or U0126     | Nrf2 nuclear protein, ARE-luc | ~60% decrease | D3T | [57] |
| U0126                 | Nrf2 nuclear entry, ARE-luc | block induction | Triphloretol-A | [58] |
| PD98059               | nuclear Nrf2 protein | block induction | eupatillin | [59] |
| PD98059               | nuclear Nrf2, ARE-luc, ARE binding | block induction | MT-III | [60] |
| U0126, DN ERK1 or DN ERK2 | HO-1 protein, ARE-luc | 30–80% decrease | 15d-PGJ2 | [61] |
| U0126                 | nuclear Nrf2 protein | block induction | EGCG | [62] |

Manipulation of MAPKs activities, by either using kinase inhibitors or genetic engineering of MAPKs by overexpressing wild-type or dominant-negative (DN) kinases, was used as the major approach to assess the role of MAPKs in Nrf2 activation. PD98059: MEK1 inhibitor; SB202190: p38 inhibitor; SB203580: p38 inhibitor; U0126: MEK1/2 inhibitor; SP600125: JNK inhibitor; luc: luciferase reporter gene; PDT: pyrroldine dithiocarbamate; β-NF: beta-naphthoflavone; BHA: tert-butylhydroxyanisole; PEITC: phenethylisothiocyanates; PDT: photodynamic therapy; 4-HNE: 4-hydroxynonenal; D3T: 3H-1,2-dithiole-3-thione; PGG: 1,2,3,4,6-penta-O-galloyl-b-D-glucose; ISMC: ileal smooth muscle cell; MTIII: metallothionein-III; EGCG: Epigallocatechin gallate.

doi:10.1371/journal.pone.0006588.t001
Transfections were performed with Lipofectamine Plus (Gibco BRL) according to the manufacturer’s instructions.

Immunoblot, immunoprecipitation, and immunofluorescence analysis
Antibodies against the HA epitope (Santa Cruz), chitin-binding domain (CBD) (New England Biolab), β-tubulin (Santa Cruz), and phosphorylated serine/threonine followed by a proline (pS/TP) (Abcam) were purchased from commercial sources. For detection of protein expression in total cell lysates, cells were lysed in sample buffer (50 mM Tris-HCl [pH 6.8], 2% SDS, 10% Glycerol, 100 mM DTT, 0.1% bromophenol blue) 48 hours following transfection. For immunoprecipitation assays, cells were lysed in RIPA buffer (10 mM sodium phosphate pH [8.0], 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS) containing 1 mM dithiothreitol (DTT), 1 mM phenylmethylsulfonyl fluoride (PMSF), and a protease inhibitor cocktail (Sigma). Cell lysates were pre-cleared with protein A beads and incubated with HA antibody-conjugated beads (Santa Cruz) or chitin beads (New England Biolab) overnight at 4°C. After washing three times with RIPA buffer, immunoprecipitated complexes were eluted in sample buffer by boiling for 5 minutes, electrophoresed through SDS-polyacrylamide gels, and subjected to immunoblot analysis. Indirect immunofluorescence analysis was performed as described before using anti-HA primary antibodies [28].

In vivo phosphorylation of Nrf2
To detect phosphorylated Nrf2 in vivo by immunoblot, transfected cells were lysed by boiling in a buffer containing 2% SDS, 150 mM NaCl, 10 mM Tris-HCl and 1 mM DTT. This rapid lysis procedure inactivated cellular phosphatases and therefore preserved phosphorylated-Nrf2 conjugates present in cells prior to lysis. These lysates were then diluted five-fold in buffer lacking SDS, followed by immunoprecipitation with HA antibody-conjugated beads.

Mass spectrometry
Mass spectrometry analysis was performed by the Harvard Taplin mass spectrometry core facility. Briefly, immunoprecipitated proteins were visualized by Coomassie staining and recovered from the gel. Excised gel bands were cut into approximately 1 mm³ pieces. Gel pieces were then subjected to a modified in-gel trypsin digestion procedure [30], followed by washing and dehydration with acetonitrile for 10 min. After removal of acetonitrile, gel pieces were completely dried in a speed-vac, and rehydrated with 50 mM ammonium bicarbonate solution containing 12.5 ng/µL modified sequencing-grade trypsin (Promega, Madison, WI) at 4°C. After 45 min., the excess trypsin solution was removed and replaced with 50 mM ammonium bicarbonate solution to just cover the gel pieces. Samples were then incubated at 37°C overnight. Peptides were later extracted by removing the ammonium bicarbonate solution, followed by one wash with a solution containing 30% acetonitrile and 5% acetic acid. The extracts were then dried in a speed-vac (~1 hr). The samples were then reconstituted in 5–10 µL of HPLC solvent A (2.5% acetonitrile, 0.1% formic acid). A nano-scale reverse-phase HPLC capillary column was created by packing 5 µm C18 spherical silica beads into a fused silica capillary (100 µm inner diameter x˜12 cm length) with a flame-drawn tip. After equilibrating the column each sample was loaded via a Famos auto sampler (LC Packings, San Francisco CA) onto the column. A gradient was formed and peptides were eluted with increasing concentrations of solvent B (97.5% acetonitrile, 0.1% formic acid).

Abolishing Nrf2 phosphorylation by mutation causes a limited decrease in the transcriptional activity of Nrf2
Genetic approaches were taken to explore the function of phosphorylation on Nrf2. Single or combined alanine substitu-
Constructions on the phosphorylation sites were constructed, and the transcriptional activity of the resultant Nrf2 mutants were tested in the ARE-dependent reporter gene assays using the ARE sequence taken from either the NQO1 gene promoter (Figure 2A) or the GSTA1 gene promoter (Figure 2B). In both cases, only the combined mutation of all five phosphorylation sites caused a slight decrease in Nrf2 transcriptional activity (Figure 2A and 2B). More importantly, none of the mutations, whether single or combined, caused obvious changes in Nrf2 protein levels (Figure 2C).

Figure 1. Nrf2 is phosphorylated in vivo at multiple sites by MAPKs. (A) HEK293T cells were cotransfected with expression vectors for HA-tagged Nrf2 and the indicated MAPKs. Cells were lysed in denaturing conditions. Cell lysates were diluted and immunoprecipitated with anti-HA antibodies. The immunoprecipitated protein was analyzed by immunoblot with antibodies specific for phosphorylated serine or threonine residues adjacent to a proline (pS/TP) (Abcam ab9344). p-Nrf2: phosphorylated Nrf2; Tub: tubulin. (B–F) Identification of distinct phosphorylation sites by tandem mass spectrometry analysis. Nrf2 proteins were purified through immunoprecipitation with anti-HA antibodies from HEK293T cells overexpressing HA-tagged Nrf2. The Nrf2 protein was size-separated by SDS-PAGE and visualized by Coomassie blue staining. The gel containing the Nrf2 protein was isolated and subjected to mass spectrometry analysis. m/z: mass to charge ratio.

doi:10.1371/journal.pone.0006588.g001
The mutant that has all five phosphorylation sites substituted by alanines was named “5A” and was subjected to subsequent analysis, since it seemed to have a slightly compromised ability in transactivating the ARE-dependent genes. Abolishment of Nrf2 phosphorylation in the Nrf2-5A mutant was confirmed by the in vivo phosphorylation assay (Figure 3A). All three MAPK consensus sites (S215, S408 and S577) seem to contribute to the overall phosphorylation level of Nrf2 in the presence of overexpressed MAPks (Figure S1). If the antibody has no bias towards the context sequences around the consensus phosphorylation sites, S408 seems to be the most dominant site. None of the single mutations was able to abolish Nrf2 phosphorylation as well as the combined 5A mutation, suggesting a redundancy in phosphorylation sites (Figure S1). To further test the effects of phosphorylation on the transcriptional activity of Nrf2, mRNA expression of Nrf2 target genes was analyzed by qRT-PCR in HEK293T cells overexpressing either Nrf2-WT (wild-type) or Nrf2-5A mutant (Figure 3C). Loss of phosphorylation causes a minor or only moderate decrease in the expression of Nrf2 downstream gene NQO1, HO-1, and GCLM (Figure 3C), without affecting Nrf2 protein levels (Figure 3B and 3C).

Phosphorylation of Nrf2 slightly increases the response of Nrf2 to several chemical inducers without affecting Keap1-mediated control of Nrf2 protein levels

To test whether phosphorylation of Nrf2 alters its behavior in response to different inducers, reporter gene analysis was performed on MDA-MB-231 cells overexpressing Keap1 and either Nrf2-WT or Nrf2-5A. Cells were treated with different Nrf2 inducers for 16 hrs prior to analysis. Altered response between Nrf2-WT and Nrf2-5A was only observed in the presence of relatively potent Nrf2 inducers (Figure 3D). The protein levels of Nrf2-WT and Nrf2-5A were increased to a similar extent in response to all inducers tested, suggesting that phosphorylation does not have any effect on Nrf2 protein stability that is primarily controlled by Keap1 (Figure 3E).

Phosphorylation of Nrf2 moderately enhances its nuclear accumulation

Nuclear translocation of Nrf2 protein is essential for Nrf2 to transactivate its downstream genes. To test whether phosphorylation of Nrf2 alters its nuclear accumulation, NIH3T3 cells were transfected with the expression vector for either HA-tagged Nrf2-WT or Nrf2-5A, along with expression vectors for CBD-tagged Keap1, and the indicated MAPK. Cell lysates were pulled-down with chitin beads and the precipitated protein complexes were analyzed by immunoblot with anti-HA and anti-CBD antibodies (Figure 4A). The interaction between Nrf2 and Keap1 was not affected by the phosphorylation status of Nrf2, consistent with the finding that phosphorylation of Nrf2 does not affect its protein stability (Figure 3E).

Figure 2. Combined alanine substitution on all phosphorylation sites causes only a moderate decrease in the transcriptional activity of Nrf2. (A) MDA-MB-231 cells were cotransfected with expression vectors for the GSTA1-ARE-dependent firefly luciferase, the TK-Renilla luciferase, and the indicated Nrf2 mutant. Luciferase reporter gene activities were analyzed using the Promega dual-luciferase reporter gene assay system. WT: wild-type; TK: thymidine kinase promoter; Inr: initiator. Relative luciferase activities and standard deviations were calculated from three independent assays. * p<0.05 when compared to WT. (B) Reporter gene assay was performed as described above using NQO1-ARE-dependent luciferase reporter gene construct in MDA-MB-231 cells. (C) Total cell lysates from one of the reporter gene assays were subjected to immunoblot analysis with anti-HA antibodies for detection of Nrf2.

doi:10.1371/journal.pone.0006588.g002
Figure 3. Genetic disruption of Nrf2 phosphorylation slightly attenuates Nrf2 activities without affecting its protein levels. (A) HEK293T cells were cotransfected with expression vectors for HA-tagged Nrf2 and JNK2. Cell lysates were immunoprecipitated with anti-HA antibodies. The immunoprecipitated protein was analyzed by immunoblot with antibodies specific for phosphorylated serine or threonine residue adjacent to a proline (pS/TP) (Abcam ab9344); wt: wild-type; 5A: the mutant with combined alanine substitution on all five phosphorylation sites. (B–C) HEK293T cells overexpressing either Nrf2-WT or Nrf2-5A were subjected to immunoblot (B) and qRT-PCR analysis (C). The error bars indicate the standard deviations calculated from triplicate samples. * p<0.05 when compared to wt. (D) MDA-MB-231 cells were cotransfected with expression vectors for the GSTA1-ARE-dependent luciferase reporter gene, Keap1, and the indicated Nrf2. Cells were treated with several Nrf2 inducers for 16 hrs prior to reporter gene analysis. tBHQ: tert-butylhydroquinone (50 μM); SF: sulforaphane (20 μM); PGJ2: 15-Deoxy-D-12,14-prostaglandin J2 (10 μM); As: sodium arsenite (20 μM); Orid: Oridonin (10 μM); Cd: cadmium chloride (20 μM); H2O2: hydrogen peroxide (500 μM). Error bars indicate standard deviations calculated from three independent assays. * p<0.05 when compared to wt in the same treatment group. (E) Total cell lysates from the above reporter gene assay were analyzed by immunoblot.

doi:10.1371/journal.pone.0006588.g003
decrease in nuclear accumulation of Nrf2-5A, compared to Nrf2-WT, in the absence of Keap1, as shown in representative pictures (Figure 4B) and quantification data (Figure 4C).

Discussion

Many previous studies have shown that MAPKs play a role in the induction of Nrf2. Table 1 summarizes key findings of all previous studies that support the involvement of MAPKs in Nrf2 activation. Manipulation of the catalytic activity of MAPKs, either through pharmaceutical intervention (kinase inhibitors) or genetic engineering (overexpression of wild-type or dominant-negative kinases, siRNA-mediated knockdown, or gene knockout), coupled with a readout of Nrf2 activity (ARE-dependent luciferase reporter gene, or Nrf2 nuclear accumulation), was used as the major approach to address the potential role of MAPKs on Nrf2 (Table 1). All three well-characterized categories of MAPKs (ERKs, JNKs, and p38) have been implicated in modulating Nrf2, with some contradictory results among different groups. Since MAPKs regulate bewilderingly diverse cellular programs, it is not clear whether the observed effects of MAPKs on Nrf2 are highly specific or just bystander effects. It remains elusive whether MAPKs regulate Nrf2 through direct phosphorylation of Nrf2 or through indirect mechanisms. Furthermore, it is not known whether or not MAPKs phosphorylate Nrf2 in vivo at all. Another key question that remains open is whether MAPKs affect Nrf2 protein stability that is primarily controlled by Keap1. Therefore, the exact role of MAPKs in Nrf2 activation, as well as the underlying molecular mechanism, remains poorly understood.

In this study, we report the first evidence that Nrf2 is phosphorylated by MAPKs in vivo. We have identified the major phosphorylation sites and used site-mutagenesis to decipher the function of direct phosphorylation of Nrf2 by MAPKs. As demonstrated by data obtained from ARE-dependent luciferase reporter gene assay and qRT-PCR analysis, a loss of Nrf2 phosphorylation caused only moderate changes in the transcriptional activity of Nrf2 (Figure 2 and 3). The Keap1-mediated control of Nrf2 protein levels was not affected by Nrf2 phosphorylation in vivo under both basal and induced conditions (Figure 3E), nor was the interaction between Nrf2 and Keap1 (Figure 4A). However, the nuclear accumulation of Nrf2 was slightly enhanced by its phosphorylation (Figure 4B and 4C). We concluded that direct phosphorylation of Nrf2 by MAPKs has a limited contribution in regulating the Nrf2-dependent antioxidant responses.

We are aware of the fact that our mass spectrometry analysis may not have identified all phosphorylated residues on Nrf2. There might be signal-induced Nrf2 phosphorylation on specific sites that were missed in the current identification procedure whereby overexpressed Nrf2 protein itself was purified from HEK293T cells under basal conditions followed by LC-MS/MS. However, the fact that the Nrf2-5A mutant has significantly decreased phosphorylation levels compared to wild-type Nrf2 in the presence of overexpressed JNK2 suggests that these five residues are the major targets of phosphorylation in vivo (Figure 3A). Neither inducible ARE-dependent transcription nor inducible Nrf2 protein levels was dramatically altered by combined mutations on the identified phosphorylation sites in the presence of several Nrf2 inducers such as tBHQ, sulforaphane, PGJ2, arsenite or cadmium, suggesting that phosphorylation at these sites has limited contribution in regulating inducible Nrf2 signaling (Figure 3D and 3F). Additionally, in an experiment without using mutations, overexpression of MAPKs failed to cause any observable effect on the interaction between wild-type Nrf2 and Keap1 (Figure 4A, lane 1–5), although Nrf2 phosphorylation was

Figure 4. Phosphorylation of Nrf2 moderately enhances its nuclear accumulation without affecting the interaction between Nrf2 and Keap1. (A) HEK293T cells were cotransfected with expression vectors for the indicated MAPKs, HA-tagged Nrf2, and CBD-tagged Keap1. Cells were harvested and lysed in RIPA buffer. Cell lysates were pulled-down with chitin beads and analyzed by immunoblot with anti-HA and anti-CBD antibodies. CBD: chitin binding domain; wt: wild-type; 5A: mutant with combined alanine substitution on all five phosphorylation sites. (B) NIH3T3 cells were transfected with expression vectors for the indicated Nrf2 protein and Keap1. The subcellular localization of Nrf2 was determined by indirect immunofluorescence analysis with anti-HA antibodies. (C) Quantification analysis of the immunofluorescence assay. At least 100 positively stained cells were examined by fluorescence microscopy. Percentages of cells in which Nrf2 was localized predominantly in the cytosol, the whole cell, or the nucleus were presented as a bar graph.

doi:10.1371/journal.pone.0006588.g004
significantly enhanced under the same conditions (Figure 1A). Collectively, these data suggest that direct phosphorylation of Nrf2 plays a limited role in regulating Nrf2 activity.

Consistent with our data, Zipper and Mulcahy showed that mutational disruption of six MAPK consensus sites in Nrf2 (including S215, S408, S577 that were also characterized in this study) failed to significantly change the GCLM ARE-dependent reporter gene activities in the absence or presence of pyrrolidine dithiocarbamate (PDTC), an Nrf2 inducer [34]. Here we provide additional evidence that mutational disruption of these sites does not dramatically alter the endogenous mRNA levels of NQO1, HO-1 or GCLM (Figure 3C), excluding possibilities that phosphorylation might interfere with molecular events that are specific to native chromosomal architectures. In addition, we showed that neither Nrf2 protein levels nor ARE-dependent luciferase activities were dramatically altered by the combined mutation in cells either left untreated or treated with divergent Nrf2 inducers, such as (BHQ, sulforaphane, PGJ2, arsinite, oridonin, cadmium and H2O2 (Figure 3E), making it a much less attractive hypothesis that phosphorylation might be involved in the action of some particular Nrf2 inducers, if not all. Furthermore, we performed a co-immunoprecipitation assay and directly demonstrated that the physical interaction between Nrf2 and Keap1 was not altered in vivo in the presence of overexpressed MAPKs or with Nrf2 phosphorylation-deficient mutants (Figure 4A). Another previous report from Kong and colleagues also showed that site-directed mutagenesis of Nrf2 at several MAPK consensus sites did not affect the transactivation activity of Nrf2, although these sites do not overlap with the sites characterized in our present study [35]. Taken together, MAPK-mediated regulation of the Nrf2 signaling pathway is not likely to be through direct phosphorylation of Nrf2.

One possible indirect mechanism is translational control on Nrf2 protein synthesis by MAPKs. MAPKs have been shown to modulate mTOR signaling pathways in controlling eukaryotic translation initiation factor 4 (eIF4) complex assembly, a critical step in Cap-dependent translational initiation, through inhibiting tuberous initiation factor 4 (eIF4) complex assembly, a critical step in Cullin-dependent translational initiation, through inhibiting tuberous sclerosis complex 2 (TSC2) and activating 90-kD ribosomal protein S6 kinases (RSKs) [36,37]. MAPKs also promote phosphorylation of eIF4E, eIF4B-BP1, and translation elongation factor 2 kinase (eEF2 kinase) through MAPK-interacting kinase 1 and 2 (MK1/2), mitogen- and stress-activated protein kinase 1 (MSK1), and MAPK-activated kinase 2/3 (MK2/3), respectively, which is thought to enhance translation of some mRNAs [38,39]. On the other hand, Nrf2 has been shown to be regulated at the translational level under several conditions [40,41]. Thus, MAPKs-mediated indirect control of Nrf2 protein synthesis, along with the moderate role of direct phosphorylation on Nrf2, may represent the underlying mechanism by which MAPKs regulates the Nrf2 signaling pathway.

Supporting Information

Figure S1 HEK293T cells were co-transfected with expression vectors for HA-Nrf2 wild-type or mutants and different kinases. Cell lysates were collected in denaturing conditions, and phosphorylation analysis was performed as described in Fig. 1A and 3A. All three sites (S215, S408 and S577) contribute to the overall phosphorylation level of Nrf2 in the presence of all four kinases.

Found at: doi:10.1371/journal.pone.0006588.s001 (0.81 MB TIF)

Figure S2 HEK293T cells were co-transfected with expression vectors for NF-kB p65, along upstream kinases IKKz and IKKb in HEK293T cells. Phosphorylation of p65 at S326 by IKKs was confirmed by an antibody that recognizes this site-specific modification (Cell Signaling, Cat# 303S). The antibody for phospho-S/TP did not pick up any signal above background, indicating the specificity of this antibody.

Found at: doi:10.1371/journal.pone.0006588.s002 (0.83 MB TIF)

Acknowledgments

We thank Drs. R. R. Vaillancourt and J. W. Regan for their kind help and reagents, Thank N. F. Villemune and A. Lau for editing of the manuscript.

Author Contributions

Conceived and designed the experiments: ZS DDZ. Performed the experiments: ZS. Analyzed the data: ZS DDZ. Wrote the paper: ZS DDZ.

References

1. Yang GS, Landau JM, Huang MT, Newmark HL (2001) Inhibition of carcinogenesis by dietary polyphenolic compounds. Am J Nutr Rev 41: 381–406.
2. Kanwar JR (2005) Anti-inflammatory immunotherapy for multiple sclerosis: experimental autoimmune encephalomyelitis (EAE) disease. Curr Med Chem 12: 2947–2962.
3. Klunig JE, Kamendulis LM (2004) The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol 44: 239–267.
4. Roed J, Peter K, Nordh TK, Runge MS, Kuhler W, et al. (1999) Oxidative stress and atherogenesis: its relationship to growth factors, thrombus formation and therapeutic approaches. Thromb Haemost 82 Suppl 1: 32–37.
5. Simonian NA, Coley JT (1996) Oxidative stress in neurodegenerative diseases. Annu Rev Pharmacol Toxicol 36: 83–106.
6. Nguyen T, Sherratt PJ, Pickard CR (2003) Regulatory mechanisms controlling gene expression mediated by the antioxidant response element. Annu Rev Pharmacol Toxicol 43: 233–260.
7. Wasserman WW, Fahl WE (1997) Functional antioxidant responsive elements. Proc Natl Acad Sci U S A 94: 5361–5366.
8. Wong PI, McMahon M, Itoh K, Yamamoto M, Hayes JD (2003) Identification of a novel Nrf2-regulated antioxidant response element (ARE) in the mouse NADPH:quinone oxidoreductase 1 gene: reassessment of the ARE consensus sequence. Biochem J 374: 357–358.
9. Alam J, Stewart D, Touchard C, Boinapally S, Choi AM, et al. (1999) Nrf2, a Cap’n’Collar transcription factor, regulates induction of the heme oxygenase-1 gene. J Biol Chem 274: 26071–26078.
10. McMahan M, Itoh K, Yamamoto M, Chana SA, Henderson CJ, et al. (2001) The Cap’n’Collar basic leucine zipper transcription factor Nrf2 (NF-E2 p45-related factor 2) controls both constitutive and inducible expression of intestinal detoxification and glutathione biosynthetic enzymes. Cancer Res 61: 3299–3307.
11. Ramos-Gomez M, Kwak MK, Dolan PM, Itoh K, Yamamoto M, et al. (2001) Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in Nrf2 transcription factor-deficient mice. Proc Natl Acad Sci U S A 98: 3410–3415.
12. Chan K, Han XD, Kan YW (2001) An important function of Nrf2 in combating oxidative stress: detoxification of acetaminophen. Proc Natl Acad Sci U S A 98: 4611–4616.
13. Cullinan SB, Gordon JD, Jin J, Harper JW, Diel JA (2004) The Keap1-BTB protein is an adaptor that bridges Nrf2 to a Cul3-based E3 ligase: oxidative stress sensing by a Cul3-Keap1 ligase. Mol Cell Biol 24: 8477–8486.
14. Furukawa M, Xiong Y (2005) BTB protein Keap1 targets antioxidant transcription factor Nrf2 for ubiquitination by the Cullin 3-Roc1 ligase. Mol Cell Biol 25: 162–171.
15. Kobayashi A, Kang MI, Okawa H, Ohtsuji M, Zenke Y, et al. (2004) Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate posttranslational degradation of Nrf2. Mol Cell Biol 24: 7130–7139.
16. Tong KD, Padmanabhan B, Kobayashi A, Shang C, Hirotsu Y, et al. (2007) Different electrostatic potentials define ETGE and DLG motifs as hinge and latch in oxidative stress response. Mol Cell Biol 27: 7531–7532.
17. Zhang DD, Lo SC, Cross JV, Templeton DJ, Hannink M (2004) Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol Cell Biol 24: 10941–10953.

Nrf2 Phosphorylation by MAPK

PLoS ONE | www.plosone.org 8 August 2009 | Volume 4 | Issue 8 | e6588
23. Sun Z, Lo SC, Sun Z, Habib GM, Lieberman MW, et al. (2005) Ubiquitination of Keap1, a BTB-Kelch substrate adaptor protein for Cul3, targets Keap1 for degradation by a proteasome-independent pathway. J Biol Chem 280: 30891–30899.

22. Hayes JD, McMahon M (2009) Nrf2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem Sci 34: 176–180.

21. Zhang DD (2006) Mechanistic studies of the Nrf2-Keap1 signaling pathway. Annu Rev Pharmacol Toxicol 46: 593–614.

20. Zhang DD, Lo SC, Sun Z, Habib GM, Lieberman MW, et al. (2005) Mechanistic studies of the Nrf2-Keap1 signaling pathway. Drug Metab Rev 37: 769–789.

22. Hayes JD, McMahon M (2009) Nrf2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem Sci 34: 176–180.

20. Zhang DD, Lo SC, Sun Z, Habib GM, Lieberman MW, et al. (2005) Mechanistic studies of the Nrf2-Keap1 signaling pathway. Drug Metab Rev 37: 769–789.

22. Hayes JD, McMahon M (2009) Nrf2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem Sci 34: 176–180.

20. Zhang DD, Lo SC, Sun Z, Habib GM, Lieberman MW, et al. (2005) Mechanistic studies of the Nrf2-Keap1 signaling pathway. Drug Metab Rev 37: 769–789.